Allied Market Research
Loading...
0

Asia-Pacific Nuclear Medicine Market Expected to Reach $8,957.89 Million by 2028

 

Report Code : A01062

quote increase in the cancer population & surge in incidences of cardiac ailments, higher efficiency of the nuclear medicines for both diagnostics and therapeutics, rise in the advancements in the radiopharmaceuticals segment contribute to the growth of the industry during the forecast period. quote

Onkar Sumant
Manager, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, “Asia-Pacific Nuclear Medicine Market by Type, Modality, Application, and End User: Regional Opportunity Analysis and Industry Forecast, 2021–2028,” the Asia-Pacific nuclear medicines market was valued at $4,116.43 million in 2020, and is projected to reach $8,957.89 billion by 2028, registering a CAGR of 10.4% from 2021 to 2028.

Radiopharmaceuticals are those radioisotopes that when bound to biological molecules, are able to target specific tissues, organs, or cells within the human body. These radioactive drugs can be used for the diagnosis and increasingly, for the therapy of diseases. A radiopharmaceutical can be observed as an entity built up having radionuclide and a vehicle molecule with high affinity or binding power toward tissue or a specific function of a human organ. Furthermore, it may comprise only the radioisotope itself if it illustrates suitable biological properties.

The Asia-Pacific nuclear medicine/radiopharmaceuticals market is poised to grow at a significant pace, owing to the demand for non-invasive techniques, availability of effective cancer treatment, and ability to observe the functioning of the organ from outside the body. Furthermore, increase in incidence of cancer & cardiovascular aliments, demand for alpha radio immunotherapy-based targeted cancer treatment, call for nuclear imaging techniques, and advancements in radiotracers may open new avenues in the radiopharmaceuticals market. Factors that drive the use of radiopharmaceuticals include change in lifestyle, elevated levels of stress, and their ability to identify various diseases sooner than other diagnostic tests. However, factors such as supply volatility & logistical challenges, stringent regulatory norms, and competition from conventional diagnostic procedures impede the Asia-Pacific nuclear medicine market growth.

The Asia-Pacific nuclear medicine market is segmented on the basis type, modality, application, end user, and country. On the basis of type, the market is divided into diagnostics, therapeutics, and biochemistry research. The diagnostics segment led the market in 2020, and is anticipated to continue this trend throughout the forecast period, owing to surge in incidence of cardiac related ailments and better imaging technique with the help of diagnostic equipment such as SPECT and PET. The increase in number of cancer patients who require early diagnosis for appropriate treatment propel the growth of diagnostics segment.

By modality, the Asia-Pacific nuclear medicine market is segregated into SPECT, PET, beta emitters, alpha emitters, brachytherapy, and others. The SPECT segment is expected to witness considerable market growth during the forecast period, owing to surge in the market for medical diagnosis such as cancer, cardiology, and neurology. Furthermore, getting multiple 2-D and 3-D images that are found by performing SPECT imaging technique helps in receiving better access in visualization and is useful for the physicians.

By application, the Asia-Pacific nuclear medicine market is segregated into oncology, cardiology, thyroid, neurology, and others. The oncology segment is expected to witness substantial market growth during the forecast period, owing to increase in advancements of radio-therapeutics which has propelled the ease in the treatment process of cancerous tumors and surge in the incidences of cancer.

By end user, the Asia-Pacific nuclear medicine market is segregated into hospitals & diagnostics centers and research institutes. The hospitals & diagnostic centers segment is expected to witness significant Asia-Pacific nuclear medicine market growth during the forecast period, owing to increased patient flow in the hospitals and the higher preference toward hospitals and diagnostic centers.

By country-wise segmentation, the market in China is expected to register the highest revenue shares during the forecast period pertaining to the presence of large targeted population base, increase in awareness regarding early diagnosis and therapeutics of cancer and cardiac ailments, and rise in disposable income. According to the statistics given by Chinese Medical Journal in 2020, China accounted for 24% of newly diagnosed cases and 30% of the cancer-related deaths worldwide in 2020. Among the 185 countries included in the database, China's age-standardized incidence rate (204.8 per 100,000) ranked 65th and the age-standardized mortality rate (129.4 per 100,000) ranked 13th. Moreover, India is anticipated to register fastest CAGR, owing to the higher cancer population base in the country.

Market players are adopting growth strategies such as product launches, mergers & acquisitions (M&As), and partnerships & collaborations to create sustainable position in the market. For instance, in March 2021, GE Healthcare unveiled StarGuide, a next-generation SPECT/CT system that uses the latest digital technologies to help clinicians improve patient outcomes in bone procedures, cardiology, neurology, oncology, and other medical specialties. The key players operating in the market are Bracco S.P.A. (Bracco Imaging S.P.A.), Bwx Technologies, Inc. (Nordion, Inc.),  Cardinal Health, Inc.,  Danaher Corporation (GE Healthcare), FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM Holdings Corporation), Ion Beam Applications (Ion Beam Applications, SA), Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.), Novartis AG (Advanced Accelerator Applications S.A.), Otsuka Holdings Co., Ltd. (ABX advanced biochemical compounds GmbH), and Siemens Healthcare GmbH.

Key Findings Of The Study

  • By type, the diagnostics segment was the highest contributor to the Asia-Pacific nuclear medicine market in 2020.
  • By modality, the SPECT segment is anticipated to register highest revenue shares during the forecast period.
  • By application, the oncology segment is anticipated to gain highest revenue shares in the coming years. 
  • By end user, hospitals & diagnostic centers segment is anticipated to gain highest revenue.
  • By country, China accounted for the largest revenue share in 2020; while India is anticipated to grow at the highest CAGR during the review period.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Tushar Nagose
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com

 
 

First time buyer?
Check offers and discount on this report
To get this report

 
Click Here
 
 

quote Asia-Pacific Nuclear Medicine Market by Type (Diagnostics, Therapeutics, and Biochemistry Research), Modality (SPECT, PET, Beta emitters, Alpha Emitters, Brachytherapy, and Others), Application (Oncology, Cardiology, Thyroid, Neurology, ad Others) and End User (Hospitals & Diagnostic Centers and Research Institutes): Regional Opportunity Analysis and Industry Forecast, 2021–2028 quote

View Report
 
 
Avenue Video Loading...

Avenue: Entire Library membership of Allied Market Research Reports at your disposal

  • Avenue is an innovative subscription-based online report database.
  • Avail an online access to the entire library of syndicated reports on more than 3,923 niche industries and company profiles on more than 12,953 firms across 11 domains.
  • A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
  • Request customizations, suggest new reports, and avail analyst support as per your requirements.
  • Get an access to the library of reports at any time from any device and anywhere.

 
 

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers

 

Featured Readings

 
rep-img

Published Date Jan 2021

Surgical Equipment Market

Download Sample
rep-img

Published Date Nov 2020

Medical Implant Market

Download Sample
 

Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

 
Get Industry Data Alerts
 

Buy Full Version
"Asia-Pacific Nuclear Medicine Market"
Purchase Enquiry